IN2014DN07813A - - Google Patents

Info

Publication number
IN2014DN07813A
IN2014DN07813A IN7813DEN2014A IN2014DN07813A IN 2014DN07813 A IN2014DN07813 A IN 2014DN07813A IN 7813DEN2014 A IN7813DEN2014 A IN 7813DEN2014A IN 2014DN07813 A IN2014DN07813 A IN 2014DN07813A
Authority
IN
India
Prior art keywords
parameter
bode
copd
prognosis
pro
Prior art date
Application number
Other languages
English (en)
Inventor
Sven Giersdorf
Michael Tamm
Daiana Stolz
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47780019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN07813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Publication of IN2014DN07813A publication Critical patent/IN2014DN07813A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/585Calcitonins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • G01N2800/122Chronic or obstructive airway disorders, e.g. asthma COPD
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN7813DEN2014 2012-03-08 2013-02-26 IN2014DN07813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12001590.4A EP2637023A1 (en) 2012-03-08 2012-03-08 Prediction of outcome in patients with chronic obstructive pulmonary disease
PCT/EP2013/000558 WO2013131621A1 (en) 2012-03-08 2013-02-26 Prediction of outcome in patients with chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
IN2014DN07813A true IN2014DN07813A (es) 2015-07-10

Family

ID=47780019

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7813DEN2014 IN2014DN07813A (es) 2012-03-08 2013-02-26

Country Status (12)

Country Link
US (1) US20150080246A1 (es)
EP (3) EP2637023A1 (es)
JP (1) JP6117251B2 (es)
CN (1) CN104126125B (es)
BR (1) BR112014019349A8 (es)
DK (1) DK2823314T3 (es)
ES (1) ES2631653T3 (es)
HK (1) HK1198556A1 (es)
IN (1) IN2014DN07813A (es)
RU (1) RU2688168C2 (es)
WO (1) WO2013131621A1 (es)
ZA (1) ZA201405610B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2637023A1 (en) 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
KR20170041907A (ko) 2014-08-14 2017-04-17 메메드 다이어그노스틱스 리미티드 매니폴드 및 초평면을 이용한 생물학적 데이터의 컴퓨터 분석법
JP6688793B2 (ja) * 2014-11-12 2020-04-28 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 被験者における慢性閉塞性肺疾患(copd)の重症度を評価するための装置及びシステムの作動方法
CA2986097A1 (en) 2015-05-18 2016-11-24 The University Of British Columbia Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd
CN108699583B (zh) 2016-03-03 2022-11-01 米密德诊断学有限公司 用于区分细菌和病毒感染的rna决定子
CN107229813A (zh) * 2016-03-24 2017-10-03 深圳中迈数字医疗技术有限公司 实施监护的判断方法及系统
US11353456B2 (en) * 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
WO2018141840A1 (en) * 2017-02-02 2018-08-09 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event
EP3610260A4 (en) * 2017-04-12 2021-01-06 ProterixBio, Inc. COMBINATIONS OF BIOMARKERS TO MONITOR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY AND / OR ASSOCIATED MECHANISMS
CN107267658B (zh) * 2017-08-21 2018-11-02 常州市第二人民医院 Copd诊断用分子标志物
JP7291688B2 (ja) * 2017-09-13 2023-06-15 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
CA3075440A1 (en) * 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh Pro-adm as a therapy monitoring marker for critcally ill patients
CN111094981B (zh) * 2017-09-13 2024-04-16 B.R.A.H.M.S有限公司 Pct和pro-adm作为监测抗生素治疗的标记物
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
CN109218131B (zh) * 2018-09-03 2022-03-29 平安医疗健康管理股份有限公司 网络监控方法、装置、计算机设备和存储介质
CN110850006B (zh) * 2019-12-20 2020-11-20 河南中医药大学 一种慢性阻塞性肺病诊断试剂及试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
SI2269063T1 (sl) * 2008-04-18 2014-01-31 Critical Care Diagnostics, Inc. Napoved tveganja večjih neugodnih pojavov na srcu
ES2431358T3 (es) * 2008-11-11 2013-11-26 B.R.A.H.M.S Gmbh Pronóstico y evaluación del riesgo en pacientes que padecen insuficiencia cardíaca mediante la determinación de la concentración de ADM
GB0911007D0 (en) * 2009-06-25 2009-08-12 Univ Hospital Of North Staffordshire Analyzer apparatus and methods for lung disease
CN102253220B (zh) * 2011-06-07 2014-04-09 复旦大学附属中山医院 用于诊断慢性阻塞性肺病急性加重期的试剂盒
EP2637023A1 (en) 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
CN104126125A (zh) 2014-10-29
BR112014019349A2 (es) 2017-06-20
EP2637023A1 (en) 2013-09-11
JP6117251B2 (ja) 2017-04-19
RU2688168C2 (ru) 2019-05-20
CN104126125B (zh) 2017-03-01
ES2631653T3 (es) 2017-09-01
RU2014140608A (ru) 2016-04-27
US20150080246A1 (en) 2015-03-19
ZA201405610B (en) 2015-12-23
DK2823314T3 (en) 2017-07-03
WO2013131621A1 (en) 2013-09-12
BR112014019349A8 (pt) 2017-07-11
EP2823314B1 (en) 2017-04-12
WO2013131621A8 (en) 2014-06-12
HK1198556A1 (en) 2015-05-15
EP3232201A1 (en) 2017-10-18
JP2015509596A (ja) 2015-03-30
EP2823314A1 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
IN2014DN07813A (es)
MX2013000675A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
MX2016006252A (es) Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono.
GB201204815D0 (en) Drilling system failure risk analysis method
EP3470848A3 (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
SG10201600502XA (en) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
RU2010145662A (ru) Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
IN2012DN02058A (es)
WO2014040891A3 (de) Verfahren zur diagnose eines molekularen phänotyps eines an einer mit chronischen entzündungen einhergehenden erkrankung leidenden patienten
WO2011150509A3 (en) Diagnosing asthma based on pentraxin-3
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
BR112013027080A2 (pt) método e aparelho para caracterizar integridade de equipamento de controle de processo
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
WO2012032511A3 (en) Kit for monitoring, detecting and staging gvhd
UA82125U (ru) Способ прогнозирования рефрактур у больных с ложными суставами
GB201020071D0 (en) Method
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.
UA95606U (uk) Спосіб прогнозування зрощення перелому
UA95605U (uk) Спосіб прогнозування зрощення перелому
UA82685U (ru) Способ лечения ложных суставов костей
UA96918U (uk) Спосіб прогнозування зрощення перелому
UA95600U (uk) Спосіб прогнозування зрощення перелому